Therapy-Related Tp53-Mutated Precursor B-Cell Acute Lymphoblastic Leukemia Arising During Lenalidomide Maintenance Following Autologous Stem Cell Transplantation for Multiple Myeloma
Article Sidebar
Main Article Content
Abstract
Therapy-related acute lymphoblastic leukemia (t-ALL) is a rare but increasingly recognized complication of cytotoxic therapy. We report a case of TP53-mutated precursor B-cell acute lymphoblastic leukemia arising in a patient with multiple myeloma treated with CyBorD induction, autologous stem cell transplantation, and prolonged lenalidomide maintenance.
The patient presented with persistent cytopenias approximately six years after transplantation. Bone marrow evaluation demonstrated Philadelphia chromosome–negative B-ALL with a TP53 mutation at high variant allele frequency. The clinical course was complicated by infectious and treatment-related toxicities, necessitating de-escalation to maintenance therapy.
This case highlights the emerging recognition of therapy-related B-ALL in multiple myeloma, the role of lenalidomide exposure, and the challenges in management due to adverse disease biology and patient-related factors.
Downloads
Article Details
Copyright (c) 2026 Rajput A.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Aldoss I, Stiller T, Tsai NC, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103(10):1662-1668. Available from: https://doi.org/10.3324/haematol.2018.193599 DOI: https://doi.org/10.3324/haematol.2018.193599
Abdulwahab A, Sykes J, Kamel-Reid S, Chang H, Brandwein JM. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012;118(16):3962-3967. Available from: https://doi.org/10.1002/cncr.26735 DOI: https://doi.org/10.1002/cncr.26735
Vasudevan Nampoothiri R, Law AD, Lam W, et al. Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. Eur J Haematol. 2020;105(1):24-29. Available from: https://doi.org/10.1111/ejh.13403 DOI: https://doi.org/10.1111/ejh.13403
Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017;28(2):228-245. Available from: https://doi.org/10.1093/annonc/mdw606 DOI: https://doi.org/10.1093/annonc/mdw606
Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333-342. Available from: https://doi.org/10.1016/s1470-2045(13)70609-0 DOI: https://doi.org/10.1016/S1470-2045(13)70609-0
Yohannan B, Langworthy BW, Turner LE, et al. Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2026. Available from: https://doi.org/10.1038/s41408-026-01537-4 DOI: https://doi.org/10.1038/s41408-026-01537-4
Geyer MB, Shaffer BC, Bhatnagar B, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv. 2023;7(13):3087-3098. Available from: https://doi.org/10.1182/bloodadvances.2022009212 DOI: https://doi.org/10.1182/bloodadvances.2022009212
Germans SK, Kulak O, Koduru P, et al. Lenalidomide-associated secondary B-lymphoblastic leukemia/lymphoma—a unique entity. Am J Clin Pathol. 2020;154(6):816-827. Available from: https://doi.org/10.1093/ajcp/aqaa109 DOI: https://doi.org/10.1093/ajcp/aqaa109
Saleem K, Franz J, Klem ML, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022;9(12):e906-e918. Available from: https://doi.org/10.1016/s2352-3026(22)00289-7 DOI: https://doi.org/10.1016/S2352-3026(22)00289-7
Boissel N, Chevret S, Huguet F, et al. Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial. Blood. 2026;147(8):821-833. Available from: https://doi.org/10.1182/blood.2025029611 DOI: https://doi.org/10.1182/blood.2025029611
Huguet F, Chevret S, Leguay T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018;36(24):2514-2523. Available from: https://doi.org/10.1200/jco.2017.76.8192 DOI: https://doi.org/10.1200/JCO.2017.76.8192
Diamond B, Ziccheddu B, Maclachlan K, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023;141(19):2359-2371. Available from: https://doi.org/10.1182/blood.2022018244 DOI: https://doi.org/10.1182/blood.2022018244
Azevedo RS, Jabbour E, Kantarjian HM, et al. Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia. Blood. 2026;147(5):547-556. Available from: https://doi.org/10.1182/blood.2025030498 DOI: https://doi.org/10.1182/blood.2025030498
National Comprehensive Cancer Network. Acute lymphoblastic leukemia. Updated July 24, 2026.
Harris EJ, Karaoglu DA, Sukhanova M, et al. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025;15(1):138. Available from: https://doi.org/10.1038/s41408-025-01350-5 DOI: https://doi.org/10.1038/s41408-025-01350-5
Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18(1):100-111. Available from: https://doi.org/10.1016/s1470-2045(16)30626-x DOI: https://doi.org/10.1016/S1470-2045(16)30626-X
DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073-2086. Available from: https://doi.org/10.1016/s0140-6736(23)00108-3 DOI: https://doi.org/10.1016/S0140-6736(23)00108-3
National Comprehensive Cancer Network. Multiple myeloma. Updated January 9, 2026.